Literature DB >> 21975269

Use of hormonal contraceptives and risk of HIV-1 transmission: a prospective cohort study.

Renee Heffron1, Deborah Donnell, Helen Rees, Connie Celum, Nelly Mugo, Edwin Were, Guy de Bruyn, Edith Nakku-Joloba, Kenneth Ngure, James Kiarie, Robert W Coombs, Jared M Baeten.   

Abstract

BACKGROUND: Hormonal contraceptives are used widely but their effects on HIV-1 risk are unclear. We aimed to assess the association between hormonal contraceptive use and risk of HIV-1 acquisition by women and HIV-1 transmission from HIV-1-infected women to their male partners.
METHODS: In this prospective study, we followed up 3790 heterosexual HIV-1-serodiscordant couples participating in two longitudinal studies of HIV-1 incidence in seven African countries. Among injectable and oral hormonal contraceptive users and non-users, we compared rates of HIV-1 acquisition by women and HIV-1 transmission from women to men. The primary outcome measure was HIV-1 seroconversion. We used Cox proportional hazards regression and marginal structural modelling to assess the effect of contraceptive use on HIV-1 risk.
FINDINGS: Among 1314 couples in which the HIV-1-seronegative partner was female (median follow-up 18·0 [IQR 12·6-24·2] months), rates of HIV-1 acquisition were 6·61 per 100 person-years in women who used hormonal contraception and 3·78 per 100 person-years in those who did not (adjusted hazard ratio 1·98, 95% CI 1·06-3·68, p=0·03). Among 2476 couples in which the HIV-1-seronegative partner was male (median follow-up 18·7 [IQR 12·8-24·2] months), rates of HIV-1 transmission from women to men were 2·61 per 100 person-years in couples in which women used hormonal contraception and 1·51 per 100 person-years in couples in which women did not use hormonal contraception (adjusted hazard ratio 1·97, 95% CI 1·12-3·45, p=0·02). Marginal structural model analyses generated much the same results to the Cox proportional hazards regression.
INTERPRETATION: Women should be counselled about potentially increased risk of HIV-1 acquisition and transmission with hormonal contraception, especially injectable methods, and about the importance of dual protection with condoms to decrease HIV-1 risk. Non-hormonal or low-dose hormonal contraceptive methods should be considered for women with or at-risk for HIV-1. FUNDING: US National Institutes of Health and the Bill & Melinda Gates Foundation.
Copyright © 2012 Elsevier Ltd. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21975269      PMCID: PMC3266951          DOI: 10.1016/S1473-3099(11)70247-X

Source DB:  PubMed          Journal:  Lancet Infect Dis        ISSN: 1473-3099            Impact factor:   25.071


  28 in total

1.  Heterosexual HIV-1 transmission after initiation of antiretroviral therapy: a prospective cohort analysis.

Authors:  Deborah Donnell; Jared M Baeten; James Kiarie; Katherine K Thomas; Wendy Stevens; Craig R Cohen; James McIntyre; Jairam R Lingappa; Connie Celum
Journal:  Lancet       Date:  2010-05-26       Impact factor: 79.321

2.  Effectiveness and safety of tenofovir gel, an antiretroviral microbicide, for the prevention of HIV infection in women.

Authors:  Quarraisha Abdool Karim; Salim S Abdool Karim; Janet A Frohlich; Anneke C Grobler; Cheryl Baxter; Leila E Mansoor; Ayesha B M Kharsany; Sengeziwe Sibeko; Koleka P Mlisana; Zaheen Omar; Tanuja N Gengiah; Silvia Maarschalk; Natasha Arulappan; Mukelisiwe Mlotshwa; Lynn Morris; Douglas Taylor
Journal:  Science       Date:  2010-07-19       Impact factor: 47.728

3.  Preexposure chemoprophylaxis for HIV prevention in men who have sex with men.

Authors:  Robert M Grant; Javier R Lama; Peter L Anderson; Vanessa McMahan; Albert Y Liu; Lorena Vargas; Pedro Goicochea; Martín Casapía; Juan Vicente Guanira-Carranza; Maria E Ramirez-Cardich; Orlando Montoya-Herrera; Telmo Fernández; Valdilea G Veloso; Susan P Buchbinder; Suwat Chariyalertsak; Mauro Schechter; Linda-Gail Bekker; Kenneth H Mayer; Esper Georges Kallás; K Rivet Amico; Kathleen Mulligan; Lane R Bushman; Robert J Hance; Carmela Ganoza; Patricia Defechereux; Brian Postle; Furong Wang; J Jeff McConnell; Jia-Hua Zheng; Jeanny Lee; James F Rooney; Howard S Jaffe; Ana I Martinez; David N Burns; David V Glidden
Journal:  N Engl J Med       Date:  2010-11-23       Impact factor: 91.245

4.  Hormonal contraception and HIV acquisition: reanalysis using marginal structural modeling.

Authors:  Charles S Morrison; Pai-Lien Chen; Cynthia Kwok; Barbra A Richardson; Tsungai Chipato; Roy Mugerwa; Josaphat Byamugisha; Nancy Padian; David D Celentano; Robert A Salata
Journal:  AIDS       Date:  2010-07-17       Impact factor: 4.177

5.  A prospective study of contraceptive use among African women in HIV-1 serodiscordant partnerships.

Authors:  Renee Heffron; Edwin Were; Connie Celum; Nelly Mugo; Kenneth Ngure; James Kiarie; Jared M Baeten
Journal:  Sex Transm Dis       Date:  2010-10       Impact factor: 2.830

6.  Genital HIV-1 RNA predicts risk of heterosexual HIV-1 transmission.

Authors:  Jared M Baeten; Erin Kahle; Jairam R Lingappa; Robert W Coombs; Sinead Delany-Moretlwe; Edith Nakku-Joloba; Nelly R Mugo; Anna Wald; Lawrence Corey; Deborah Donnell; Mary S Campbell; James I Mullins; Connie Celum
Journal:  Sci Transl Med       Date:  2011-04-06       Impact factor: 17.956

Review 7.  Sex steroid hormones, hormonal contraception, and the immunobiology of human immunodeficiency virus-1 infection.

Authors:  Zdenek Hel; Elizabeth Stringer; Jiri Mestecky
Journal:  Endocr Rev       Date:  2009-11-10       Impact factor: 19.871

8.  Successful increase in contraceptive uptake among Kenyan HIV-1-serodiscordant couples enrolled in an HIV-1 prevention trial.

Authors:  Kenneth Ngure; Renee Heffron; Nelly Mugo; Elizabeth Irungu; Connie Celum; Jared M Baeten
Journal:  AIDS       Date:  2009-11       Impact factor: 4.177

9.  Acyclovir and transmission of HIV-1 from persons infected with HIV-1 and HSV-2.

Authors:  C Celum; A Wald; J R Lingappa; A S Magaret; R S Wang; N Mugo; A Mujugira; J M Baeten; J I Mullins; J P Hughes; E A Bukusi; C R Cohen; E Katabira; A Ronald; J Kiarie; C Farquhar; G J Stewart; J Makhema; M Essex; E Were; K H Fife; G de Bruyn; G E Gray; J A McIntyre; R Manongi; S Kapiga; D Coetzee; S Allen; M Inambao; K Kayitenkore; E Karita; W Kanweka; S Delany; H Rees; B Vwalika; W Stevens; M S Campbell; K K Thomas; R W Coombs; R Morrow; W L H Whittington; M J McElrath; L Barnes; R Ridzon; L Corey
Journal:  N Engl J Med       Date:  2010-01-20       Impact factor: 91.245

10.  Viral linkage in HIV-1 seroconverters and their partners in an HIV-1 prevention clinical trial.

Authors:  Mary S Campbell; James I Mullins; James P Hughes; Connie Celum; Kim G Wong; Dana N Raugi; Stefanie Sorensen; Julia N Stoddard; Hong Zhao; Wenjie Deng; Erin Kahle; Dana Panteleeff; Jared M Baeten; Francine E McCutchan; Jan Albert; Thomas Leitner; Anna Wald; Lawrence Corey; Jairam R Lingappa
Journal:  PLoS One       Date:  2011-03-02       Impact factor: 3.240

View more
  214 in total

1.  Specificity of four laboratory approaches for cross-sectional HIV incidence determination: analysis of samples from adults with known nonrecent HIV infection from five African countries.

Authors:  Oliver Laeyendecker; Ron Brookmeyer; Caroline E Mullis; Deborah Donnell; Jairam Lingappa; Connie Celum; Jared M Baeten; Mary S Campbell; Max Essex; Guy de Bruyn; Carey Farquhar; Thomas C Quinn; Susan H Eshleman
Journal:  AIDS Res Hum Retroviruses       Date:  2012-10       Impact factor: 2.205

2.  Risk Factors for HIV Acquisition in High Risk Women in a Generalised Epidemic Setting.

Authors:  Nivashnee Naicker; Ayesha B M Kharsany; Lise Werner; Francois van Loggerenberg; Koleka Mlisana; Nigel Garrett; Salim S Abdool Karim
Journal:  AIDS Behav       Date:  2015-07

3.  The contraceptive depot medroxyprogesterone acetate impairs mycobacterial control and inhibits cytokine secretion in mice infected with Mycobacterium tuberculosis.

Authors:  Léanie Kleynhans; Nelita Du Plessis; Nasiema Allie; Muazzam Jacobs; Martin Kidd; Paul D van Helden; Gerhard Walzl; Katharina Ronacher
Journal:  Infect Immun       Date:  2013-02-04       Impact factor: 3.441

Review 4.  Comparison of the vaginal environment of Macaca mulatta and Macaca nemestrina throughout the menstrual cycle.

Authors:  Sarah V Hadzic; Xiaolei Wang; Jason Dufour; Lara Doyle; Preston A Marx; Andrew A Lackner; Daniel B Paulsen; Ronald S Veazey
Journal:  Am J Reprod Immunol       Date:  2014-02-13       Impact factor: 3.886

5.  Effect of hormonal contraception on the function of plasmacytoid dendritic cells and distribution of immune cell populations in the female reproductive tract.

Authors:  Katherine G Michel; Richard P H Huijbregts; Jonathan L Gleason; Holly E Richter; Zdenek Hel
Journal:  J Acquir Immune Defic Syndr       Date:  2015-04-15       Impact factor: 3.731

6.  Preexposure prophylaxis is efficacious for HIV-1 prevention among women using depot medroxyprogesterone acetate for contraception.

Authors:  Renee Heffron; Nelly Mugo; Edwin Were; James Kiarie; Elizabeth A Bukusi; Andrew Mujugira; Lisa M Frenkel; Deborah Donnell; Allan Ronald; Connie Celum; Jared M Baeten
Journal:  AIDS       Date:  2014-11-28       Impact factor: 4.177

7.  Objective Measurement of Inaccurate Condom Use Reporting Among Women Using Depot Medroxyprogesterone Acetate for Contraception.

Authors:  Renee Heffron; Urvi M Parikh; Kerri J Penrose; Nelly Mugo; Deborah Donnell; Connie Celum; John W Mellors; Jared M Baeten
Journal:  AIDS Behav       Date:  2017-07

Review 8.  Contraception for HIV-Infected Adolescents.

Authors:  Athena P Kourtis; Ayesha Mirza
Journal:  Pediatrics       Date:  2016-09       Impact factor: 7.124

9.  Levonorgestrel in contraceptives and multipurpose prevention technologies: does this progestin increase HIV risk or interact with antiretrovirals?

Authors:  Chelsea B Polis; Sharon J Phillips; Sharon L Hillier; Sharon L Achilles
Journal:  AIDS       Date:  2016-11-13       Impact factor: 4.177

Review 10.  Drug-Drug Interactions, Effectiveness, and Safety of Hormonal Contraceptives in Women Living with HIV.

Authors:  Kimberly K Scarsi; Kristin M Darin; Catherine A Chappell; Stephanie M Nitz; Mohammed Lamorde
Journal:  Drug Saf       Date:  2016-11       Impact factor: 5.606

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.